Nicotinamide as a therapeutic agent for bone diseases

키워드

참고문헌 (49)

1. Rolfe HM, "A review of nicotinamide : treatment of skin diseases and potential side effects", J Cosmet Dermatol, 13, pp.324~328 (2014)[DOI]
2. Chen AC, "A phase 3 randomized trial of nicotinamide for skin-cancer chemoprevention", N Engl J Med, 373, pp.1618~1626 (2015)[DOI]
3. Iqbal T, "The therapeutic perspective of NAD+precursors in age-related diseases", Biochem Biophys Res Commun, 702, pp.149590~ (2024)[DOI]
4. Srivastava S, "Emerging therapeutic roles for NAD+ metabolism in mitochondrial and age-related disorders", Clin Transl Med, 5, pp.25~ (2016)[DOI]
5. Mitchell SJ, "Nicotinamide improves aspects of healthspan, but not lifespan, in mice", Cell Metab, 27, pp.667~676 (2018)[DOI]
6. Imai S, "Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase", Nature, 403, pp.795~800 (2000)[DOI]
7. Avalos JL, "Mechanism of sirtuin inhibition by nicotinamide : altering the NAD+ cosubstrate specificity of a Sir2 enzyme", Mol Cell, 17, pp.855~868 (2005)[DOI]
8. Hwang ES, "Nicotinamide is an inhibitor of SIRT1 in vitro, but can be a stimulator in cells", Cell Mol Life Sci, 74, pp.3347~3362 (2017)[DOI]
9. Meng Y, "Nicotinamide promotes cell survival and differentiation as kinase inhibitor in human pluripotent stem cells", Stem Cell Reports, 11, pp.1347~1356 (2018)[DOI]
10. Ma L, "SIRT1 and SIRT2 inhibition impairs pediatric soft tissue sarcoma growth", Cell Death Dis, 5, pp.e1483~ (2014)[DOI]
11. Hill LJ, "Meat intake and the dose of vitamin B3-nicotinamide : cause of the causes of disease transitions, health divides, and health futures?", Int J Tryptophan Res, 10, pp.1178646917704662~ (2017)[DOI]
12. Hołubiec P, "Pathophysiology and clinical management of pellagra-a review", Folia Med Cracov, 61, pp.125~137 (2021)[DOI]
13. Kaymak Y, "An investigation of efficacy of topical niacinamide for the treatment of mild and moderate acne vulgaris", J Turk Acad Dermatol, 2, pp.jtad82402a~ (2008)
14. Hakozaki T, "The effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer", Br J Dermatol, 147, pp.20~31 (2002)[DOI]
15. Soma Y, "Moisturizing effects of topical nicotinamide on atopic dry skin", Int J Dermatol, 44, pp.197~202 (2005)[DOI]
16. Elliott RB, "A population based strategy to prevent insulin-dependent diabetes using nicotinamide", J Pediatr Endocrinol Metab, 9, pp.501~509 (1996)[DOI]
17. Yoon H, "Nicotinamide improves delayed tooth eruption in Runx2+", -mice, 2021, pp.100, 423~431
18. Damian DL, "Nicotinamide for skin cancer chemoprevention", Australas J Dermatol, 58, pp.174~180 (2017)[DOI]
19. Wise GE, "Mechanisms of tooth eruption and orthodontic tooth movement", J Dent Res, 87, pp.414~434 (2008)[DOI]
20. Heinrich J, "CSF-1, RANKL and OPG regulate osteoclastogenesis during murine tooth eruption", Arch Oral Biol, 50, pp.897~908 (2005)[DOI]
21. Ida-Yonemochi H, "Disturbed tooth eruption in osteopetrotic(op", op)mice : histopathogenesis of tooth malformation and odontomas, 2002, pp.31, 361~373
22. Sheng ZF, "OPG knockout mouse teeth display reduced alveolar bone mass and hypermineralization in enamel and dentin", Arch Oral Biol, 55, pp.288~293 (2010)[DOI]
23. Boyce BF, "Functions of RANKL", RANK, Arch Biochem Biophys, pp.2008, 473[DOI]
24. Sai Charan KV, "The tooth eruption and its abnormalities-a narrative review", SRM J Res Dent Sci, 13, pp.109~114 (2022)[DOI]
25. Suri L, "Delayed tooth eruption : pathogenesis, diagnosis, and treatment. A literature review", Am J Orthod Dentofacial Orthop, 126, pp.432~445 (2004)[DOI]
26. Ray JG, "Noneruption of teeth in amelogenesis imperfecta : a report of two cases and review", J Oral Maxillofac Pathol, 26, pp.254~258 (2022)[DOI]
27. Kaloust S, "Dental development in Apert syndrome", Cleft Palate Craniofac J, 34, pp.117~121 (1997)[DOI]
28. Kreiborg S, "Tooth formation and eruption-lessons learnt from cleidocranial dysplasia", Eur J Oral Sci, 126(Suppl 1), pp.72~80 (2018)[DOI]
29. Canger EM, "Amelogenesis imperfecta, hypoplastic type associated with some dental abnormalities : a case report", Braz Dent J, 21, pp.170~174 (2010)[DOI]
30. Hohoff A, "The spectrum of Apert syndrome : phenotype, particularities in orthodontic treatment, and characteristics of orthognathic surgery", Head Face Med, 3, pp.10~ (2007)[DOI]
31. Kim HJ, "Post-translational regulations of transcriptional activity of RUNX2", Mol Cells, 43, pp.160~167 (2020)[DOI]
32. Ryoo HM, "RUNX2 mutations in cleidocranial dysplasia patients", Oral Dis, 16, pp.55~60 (2010)[DOI]
33. Kim WJ, "RUNX2-modifying enzymes : therapeutic targets for bone diseases", Exp Mol Med, 52, pp.1178~1184 (2020)[DOI]
34. Barth FA, "Therapeutic protocol for orthosurgical management of class III malocclusion in patients with cleidocranial dysostosis", J Craniofac Surg, 29, pp.1642~1647 (2018)[DOI]
35. Roberts T, "Cleidocranial dysplasia : a review of the dental, historical, and practical implications with an overview of the South African experience", Oral Surg Oral Med Oral Pathol Oral Radiol, 115, pp.46~55 (2013)[DOI]
36. Yoda S, "Delayed tooth eruption and suppressed osteoclast number in the eruption pathway of heterozygous Runx2", Cbfa1 knockout mice, 2004, pp.49, 435~442
37. Martínez-Reyes I, "Mitochondrial TCA cycle metabolites control physiology and disease", Nat Commun, 11, pp.102~ (2020)[DOI]
38. Suh J, "Mitochondrial fragmentation and donut formation enhance mitochondrial secretion to promote osteogenesis", Cell Metab, 35, pp.345~360 (2023)[DOI]
39. Yoon H, "Nicotinamide enhances osteoblast differentiation through activation of the mitochondrial antioxidant defense system", Exp Mol Med, 55, pp.1531~1543 (2023)[DOI]
40. Kim HJ, "ROS-induced PADI2downregulation accelerates cellular senescence via the stimulation of SASP production and NFκB activation", Cell Mol Life Sci, 79, pp.155~ (2022)[DOI]
41. Verdin E, "NAD+ in aging, metabolism, and neurodegeneration", Science, 350, pp.1208~1213 (2015)[DOI]
42. Covarrubias AJ, "NAD+ metabolism and its roles in cellular processes during ageing", Nat Rev Mol Cell Biol, 22, pp.119~141 (2021)[DOI]
43. Song J, "Nicotinamide mononucleotide promotes osteogenesis and reduces adipogenesis by regulating mesenchymal stromal cells via the SIRT1 pathway in aged bone marrow", Cell Death Dis, 10, pp.336~ (2019)[DOI]
44. Liang H, "Nicotinamide mononucleotide alleviates Aluminum induced bone loss by inhibiting the TXNIP-NLRP3 inflammasome", Toxicol Appl Pharmacol, 362, pp.20~27 (2019)[DOI]
45. Huang RX, "Nicotinamide mononucleotide attenuates glucocorticoid‑induced osteogenic inhibition by regulating the SIRT1", PGC‑1α signaling pathway, 2020, pp.22, 145~154
46. Kim HN, "A decrease in NAD+ contributes to the loss of osteoprogenitors and bone mass with aging", NPJ Aging Mech Dis, 7, pp.8~ (2021)[DOI]
47. Ling M, "Epigenetic regulation of Runx2 transcription and osteoblast differentiation by nicotinamide phosphoribosyltransferase", Cell Biosci, 7, pp.27~ (2017)[DOI]
48. Li Y, "Nampt expression increases during osteogenic differentiation of multi-and omnipotent progenitors", Biochem Biophys Res Commun, 434, pp.117~123 (2013)[DOI]
49. Hassan B, "NAMPT expression in osteoblasts controls osteoclast recruitment in alveolar bone remodeling", J Cell Physiol, 233, pp.7402~7414 (2018)[DOI]

관련 논문AI추천